With $25 million pledged from a stock sale to institutional investors, rare-disease specialist Retrophin Inc. signed a deal with an unidentified pharma firm for an option to license its autism/schizophrenia drug and said plans for a potentially pivotal trial are on track for RE-021, the firm's dual-acting receptor antagonist of angiotensin and endothelin receptors, as a therapy for focal segmental glomerulosclerosis (FSG).